Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Macugen Approved for AMD in Europe | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Macugen Approved for AMD in Europe

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer has been granted marketing authorization for Macugen for the treatment of neovascular (wet) age- related macular degeneration (AMD) by the European Commission. Macugen is the first treatment to target the underlying disease process and has been proven to help preserve visual acuity in patients with wet AMD. Clinical studies showed that Macugen prevented severe vision loss at twice the rate of standard care, which included photodynamic therapy.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters